J. Michael White

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Axel Hauschild, Sanjiv S. Agarwala, Uwe Trefzer et al. · Journal of Clinical Oncology · 2009 · 540 citations · Full text

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

David F. McDermott, Jeffrey A. Sosman, René González et al. · Journal of Clinical Oncology · 2008 · 249 citations

The Integration of Sex and Gender Considerations Into Biomedical Research: Lessons From International Funding Agencies

J. Michael White, Cara Tannenbaum, Ineke Klinge et al. · The Journal of Clinical Endocrinology & Metabolism · 2021 · 163 citations · Full text

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Neil L. Berinstein, Gregory T. Wolf, Paul H. Naylor et al. · Cancer Immunology Immunotherapy · 2011 · 42 citations · Full text

Lymphoid Neoplasia, Irx-2 Immunotherapy Regimen, Neck Cancer +11

The gender health innovation gap: A perspective from the NIH Office of Research on Women’s Health

J. Michael White, Janine A. Clayton · Med · 2022 · 14 citations